Receive a complete Daily History of this Stock You can receive a complete daily file of this issue since 1970 or stock inception. We will email you the file in ASCII format within a few hours or ordering. Product Details | Order

Business Description
Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies primarily in the areas of oncology, neurology, and immunology in the United States and internationally. Its product portfolio comprises AVONEX and TYSABRI for the treatment of relapsing forms of multiple sclerosis; RITUXAN for the treatment of relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphomas, or B-cell NHLs; ZEVALIN, a radio immunotherapy for relapsed or refractory low-grade, follicular, or transformed B-cell NHL; and FUMADERM, an immunomudulator for the treatment of severe psoriasis. The company's other products under development include BG-12, a Phase III clinical trial product for the treatment of multiple sclerosis and psoriasis; Anti-CD80, a Phase III clinical product for relapsed or refractory NHL; and Anti-CD23, a Phase IIb clinical trial product for the treatment of relapsed or refractory CLL. Biogen Idec has collaboration agreements with PDL BioPharma, Inc., Sunesis Pharmaceuticals, Inc., Vernalis plc, Vetter Pharma-Fertigung GmbH & Co. KG, Elan Corporation plc, Alnylam Pharmaceuticals, Inc., UCB SA, and Schering AG. It also has an agreement with Cardiokine, Inc. to develop lixivaptan, an oral compound for the potential treatment of hyponatremia in patients with congestive heart failure. The company was founded in 1985 and is based in Cambridge, Massachusetts.